Companhia Siderurgica Nacional Sponsored ADR Aktie News

Companhia Siderúrgica Nacional (SID) Q1 2026 Earnings Call Transcript

New immunologic and biomarker data supports the potential of ITK inhibition with soquelitinib to increase persistent Treg cells and influence multiple inflammatory pathways. Data supports potential for soquelitinib to rebalance the immune system and produce drug-free remissions following discontinuation of therapy Immunologic markers consistent with soquelitinib's novel mechanism of action and ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DeepBiology--TRexBio to Present Late-Breaking Data at SID 2026 Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis.

Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors  WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the presentation of Phase...

SÃO PAULO, April 30, 2026 /PRNewswire/ -- Companhia Siderúrgica Nacional (NYSE: SID and B3: CSNA3) ("CSN") has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission on April 30, 2026. Shareholders and holders of American depositary shares representing CSN's shares have the ability to, upon request to CSN's Investor Rela...

Companhia Siderúrgica Nacional (SID) Q4 2025 Earnings Call Transcript

Companhia Siderúrgica Nacional (SID) Shareholder/Analyst Call Transcript